Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
West Pharmaceutical (WST) delivered earnings and revenue surprises of +13.94% and +4.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) reported Q2 adjusted earnings Thursday of $2.37 per diluted share
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results tomorrow before market open. Here’s what to expect.
CAH is set to buy two home-care businesses for about $360 million, expanding diabetes and urology reach while targeting first-year EPS accretion.
RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.
West Pharmaceutical Services stock has delivered a 64.7% return over the past year, yet the valuation checks and current pricing suggest it may no longer be an obvious bargain, with the Discounted Cash Flow (DCF) estimate pointing to a level that is roughly in line with where the shares trade today. After such a strong run, investors are weighing solid business developments against signals that the stock screens as expensive on several measures. Over the past 1 year, West Pharmaceutical...
WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.
OMCL heads into Q2 earnings with OmniSphere adoption, Connected Devices execution and recurring revenue growth ahead of July 30 results.
GE HealthCare's MIM Anyware offers secure browser-based imaging access to streamline workflows, collaboration and clinical decision-making.
Wall Street closed lower on Monday, pulled down by healthcare and industrial stocks.
Besides Wall Street's top-and-bottom-line estimates for West Pharmaceutical (WST), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
MMSI vs. WST: Which Stock Is the Better Value Option?
ALGN reports Q2 results on July 29, with investors watching Clear Aligner growth as higher volumes and digital offerings shape quarterly performance.
BLCO launches EyeGility in the United States, pairing preloaded enVista Aspire lenses with smoother handling, one-handed use and surgical flexibility.
ISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.
Inspire Medical's Inspire V rollout, broader approvals and clinical evidence support growth despite coding and reimbursement pressures.
GE HealthCare's shares rise about 4% after unveiling a $500M, 10-year alliance to deploy 1,300 technologies across Catholic Health.
On July 14, 2026, Daikyo Seiko, Ltd. entered into two 10‑year Distributorship Agreements with West Pharmaceutical Services, making West the exclusive distributor of Daikyo products outside Japan and appointing Daikyo as a non‑exclusive distributor of West products in Japan, both with early termination options under specific conditions. This long-term cross-distribution structure deepens an existing partnership and could meaningfully reshape West’s global access to high-value injectable...
West Pharmaceutical Services (WST) is back in focus after signing two long term distributorship agreements with Daikyo Seiko, expanding its role as exclusive distributor of Daikyo products outside Japan. See our latest analysis for West Pharmaceutical Services. Alongside the Daikyo agreements, West Pharmaceutical Services has been in focus ahead of its upcoming July 23 earnings release, with the stock showing a 30 day share price return of 8.32% and a 1 year total shareholder return of...
DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.
SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.
HQY benefits from strong HSA growth, AI-driven automation and solid first-quarter fiscal 2027 results despite data security risks.
GUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical is riding on strong HVP demand, GLP-1 growth and Annex 1 adoption, but can these tailwinds outweigh capacity and concentration risks?
ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.
NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and investments may pressure near-term profits.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
